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OBJECTIVE — Neuropathic pain due to small-ﬁber sensory neuropathy in type 2 diabetes
can be diagnosed by skin biopsy with quantiﬁcation of intra-epidermal nerve ﬁber (IENF)
density.Thereis,however,alackofnoninvasivephysiologicalassessment.Contactheat–evoked
potential (CHEP) is a newly developed approach to record cerebral responses of A ﬁber–
mediated thermonociceptive stimuli. We investigated the diagnostic role of CHEP.
RESEARCH DESIGN AND METHODS — From 2006 to 2009, there were 32 type 2
diabeticpatients(20malesand12females,aged51.6310.93years)withskindenervationand
neuropathic pain. CHEPs were recorded with heat stimulations at the distal leg, where skin
biopsy was performed.
RESULTS — CHEP amplitude was reduced in patients compared with age- and sex-matched
control subjects (14.8  15.6 vs. 33.7  10.1 V, P  0.001). Abnormal CHEP patterns
(reduced amplitude or prolonged latency) were noted in 81.3% of these patients. The CHEP
amplitudewasthemostsigniﬁcantparametercorrelatedwithIENFdensity(P0.003)andpain
perception to contact heat stimuli (P  0.019) on multiple linear regression models. An excit-
ability index was derived by calculating the ratio of the CHEP amplitude over the IENF density.
This excitability index was higher in diabetic patients than in control subjects (P  0.023),
indicating enhanced brain activities in neuropathic pain. Among different neuropathic pain
symptoms, the subgroup with evoked pain had higher CHEP amplitudes than the subgroup
without evoked pain (P  0.011).
CONCLUSIONS — CHEP offers a noninvasive approach to evaluate the degeneration of
thermonociceptive nerves in diabetic neuropathy by providing physiological correlates of skin
denervation and neuropathic pain.
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T
ype 2 diabetic neuropathy is fre-
quently complicated with neuro-
pathic pain, suggesting the
involvement of small-diameter ther-
monociceptive nerves (1). Two ap-
proaches have been developed for the
diagnosisofsmall-ﬁbersensoryneurop-
athy: psychophysical assessments by
measuring thermal thresholds on quan-
titative sensory testing (2,3) and patho-
logical evaluations by quantifying intra-
epidermal nerve ﬁber (IENF) density in
punch skin biopsies (4–6). These ex-
aminations provide psychophysical and
neuropathological evidence of small-
diameter thermonociceptive nerve de-
generation and serve as the deﬁnition of
small-ﬁber sensory neuropathy (7,8).
These two tests are sensitive in detect-
ing the negative symptoms of diabetic
neuropathy, for example, the elevation
of thermal thresholds (9). However, the
neurophysiological correlates of these
tests with positive symptoms such as
neuropathic pain are limited, and the
physiological consequences of ther-
monociceptive nerve involvements in
diabetic neuropathy have rarely been
explored.
In recent years, several groups, in-
cluding our own, have established con-
tact heat–evoked potential (CHEP) as a
clinically feasible approach to examine
the physiology of thermonociceptive
nerves (10,11). CHEP, by activating A
ﬁbers, can be recorded at the vertex for
clinical use (12). Thus, CHEPs provide a
noninvasivetechniquetoobjectivelyeval-
uate the physiology of thermonociceptive
nerve dysfunctions. This approach raises
the possibility of whether CHEP can be a
noninvasive diagnostic tool complemen-
tary to IENF density and thermal thresh-
olds and whether CHEP parameters can
reﬂect the neurophysiological correlates
of reduced IENF density in diabetic neu-
ropathy. Additionally, since the CHEP
amplitude parallels the perceived inten-
sity of heat pain in normal subjects
(11,13), a further critical issue is whether
CHEP could demonstrate positive symp-
toms or signs of neuropathic pain in dia-
betic neuropathy. These include the
spontaneous forms, such as a burning
sensation, and the evoked forms, such as
hyperalgesia to thermal stimuli.
To address the above issues, our
study investigated the following: 1) the
changesinCHEPanditsdiagnosticrolein
diabeticneuropathy,2)thecorrelationsof
CHEPwiththeskininnervationandther-
mal thresholds, and 3) the relationship of
CHEP and neuropathic pain in diabetic
neuropathy.
RESEARCH DESIGN AND
METHODS— The study population
consisted exclusively of type 2 diabetic
patientswithneuropathicpainreferredto
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Taiwan University Hospital, Taipei, Tai-
wan, from January 2006 to December
2009. The inclusion criteria were 1) sym-
metrical neuropathic pain symptoms in
the feet with a graded stocking pattern of
distribution and 2) degeneration of ther-
monociceptive nerves with reduced IENF
density on skin biopsy at the leg. The fea-
tures of neuropathic pain in the feet and
legs were further categorized as evoked
pain (thermal hyperalgesia and touch-
induced allodynia), tingling (or shoot-
ing), lacerating, hot (or burning), cold (or
freezing), electric shock, and numbness.
Neurological examinations followed rou-
tineprocedureswithdetailedassessments
of the sensations to heat, cold, pinprick,
and vibratory stimuli. Patents with weak-
ness of limbs were excluded. There were
32 diabetic patients (20 males and 12 fe-
males)aged51.610.9years(range22–
65) fulﬁlling the above criteria, i.e., with
symmetric neuropathic pain symptoms
and pathological evidence of skin dener-
vation. The duration of diabetes was
8.25  6.60 years (range 0.25–26), and
the duration of neuropathic pain was
1.79  1.96 years (range 0.1–7). Data of
glycemic control including fasting and
2-hpostprandialglucoselevelsandA1C3
yearsbeforeourevaluationwereanalyzed
for patients with diabetes duration longer
than 3 years. For those patients with dia-
betes duration shorter than 3 years, all
databeforetheskinbiopsywerecollected
for analysis.
The Ethics Committee of National
TaiwanUniversityHospitalapprovedthis
study. Informed consent was obtained
from each subject before the procedures.
Each patient had received skin bi-
opsy, CHEP, quantitative sensory testing,
and nerve conduction study. All these
tests followed established protocols and
are detailed in the METHODS section in the
online appendix (available at http://care.
diabetesjournals.org/cgi/content/full/
dc10-1135/DC1). Results were interpreted
according to our previously described nor-
mative databases (14,15).
Analysis of CHEP
The analysis of CHEP waveforms was
based on an averaged tracing of the ﬁrst
16 artifact-free tracings (detailed in the
online appendix) using the Nicolet EP
Vue system (Nicolet Biomedical, Madi-
son, WI). In normal subjects, the control
tests showed no recognizable waveforms,
and contact heat stimulation of the lateral
leg evoked well-deﬁned waveforms at Cz
withaninitialnegativepeak(N-wave)fol-
lowed by a positive peak (P-wave) as de-
scribed previously (10,15). We measured
the N-wave latency as the CHEP latency
and the amplitude between the N-wave
andP-waveastheCHEPamplitude.Since
the reporting of our normative data (15),
we have continuously updated normative
valuesofCHEPeveryyear.Thenormative
databasenowconsistedof92healthysub-
jects (40 men and 52 women) aged
40.6  12.0 years (range 22–65). The
updated normative values were 448.4 
34.4 and 506.4 ms for CHEP latency
(mean  SD and 95th percentile) and
38.6  11.2 and 25.4 V for CHEP am-
plitude (mean  SD and 5th percentile).
The CHEP amplitude and the IENF
densityassesstwodifferentdimensionsof
neuropathy. Two observations mandate
the necessity for an index to integrate
these two independent parameters and to
investigate the relationship between the
CHEP amplitude and IENF density in di-
abetic painful neuropathy. First, CHEP
represents the cerebral responses to ther-
mal pain stimuli and is highly correlated
with pain perception (11,13). Second,
CHEP is generated through the activation
ofcutaneousterminalsofthermonocicep-
tive small-ﬁber nerves and therefore is af-
fected by changes in IENF density. IENF
represents the nociceptive input and
CHEP reﬂects the output from nocicep-
tive stimuli. To investigate whether there
was ampliﬁcation in signals from the in-
put to the output between control sub-
jects and diabetic patients, we deﬁned an
excitability index. The excitability index
was calculated by normalizing CHEP am-
plitude to the IENF density, i.e., the ratio
of the CHEP amplitude over the IENF
density.BecausetheIENFdensityisinthe
denominator and IENF densities are cal-
culated to the ﬁrst decimal place, the
IENF density was deﬁned as 0.1 ﬁ-
bers/mm if the skin was completely de-
nervated in calculating the excitability
index.
Study design and data analysis
Data of the 32 patients were compared
withdataof32age-andsex-matchedsub-
jects (15 men and 17 women, aged
47.1  15.1 years; P  0.22 for sex and
P  0.18 for age). All had normal IENF
density(8.82.4ﬁbers/mm).Numerical
variables are expressed as the mean  SD
and were compared with t tests if the data
followed a Gaussian distribution. If the
samplesizewassmall,thenumericalvari-
ables were compared using the nonpara-
metric test (Wilcoxon rank sum test).
Correlations between variables were
graphically analyzed using the slope of
the regression line, including the 95% CI.
Thecorrelationwasfurtherexploredwith
a multiple linear regression analysis, and
the covariance of the model R
2 and the
standardized correlation coefﬁcient are
presented. All analyses were performed
using Stata software (StataCorp LP, Col-
legeStation,TX).Resultswereconsidered
signiﬁcant at P  0.05.
RESULTS
Clinical presentations
The demographic data, diabetic status,
andneuropathicpainproﬁlesaresumma-
rized in supplementary Table A1 in the
online appendix. The symptoms of neu-
ropathic pain were diverse, ranging from
evoked pain (10, 31.3%) to numbness
(25, 78.1%). Based on neurological ex-
aminations, 29 (90.6%) had impaired
senses mediated by small ﬁbers (pin-
prick, heat, and coldness) and 21
(65.6%) patients had dysfunction of
large ﬁbers (vibration).
The IENF density was reduced in all
these patients: 1.1  1.5 ﬁbers/mm
(range 0–5.7 ﬁbers/mm). In total, 27 pa-
tients (84.4%) had elevated thermal
thresholds on quantitative sensory test-
ing: 26 with elevated warm thresholds
and 9 with elevated cold thresholds at the
foot dorsum. For large ﬁbers with nerve
conduction study, 16 patients (50%) had
reduced sensory action potential ampli-
tudes or decreased conduction velocities
in the sural nerve, and 21 (65.6%) had
reduced CMAP amplitude or decreased
conduction velocity in the peroneal
nerve.
CHEP in diabetic neuropathy
To explore the neurophysiological
changes due to thermonociceptive nerve
degeneration in type 2 diabetes, we ana-
lyzed CHEP parameters in these patients.
CHEP amplitudes were reduced in dia-
betic patients compared with age- and
sex-matched control subjects (14.8 
15.6vs.33.710.1V,P0.001),and
26 patients (81.3%) had abnormal CHEP
patterns. Among them, 13 patients had
absence of CHEP waveform, and all of
themhadeithercompletedenervation(in
9 cases) or very low IENF density (in 4
caseswithIENFdensityof0.2–0.9ﬁbers/
mm); 10 had reduced CHEP amplitude;
and9hadprolongedCHEPlatencies.The
mean intensity of pain perception on the
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the range of mild pain. A representative
patientwithabnormalCHEPisillustrated
in Fig. 1A and C. In this 60-year-old fe-
male patient with diabetic painful neuropa-
thy and an IENF density of 0.9 ﬁbers/mm,
the CHEP latency was mildly prolonged
(507 ms) and the CHEP amplitude was re-
duced (19.3 V) when compared with the
typical N- and P-waves, which could be
elicited in an age- and sex-matched healthy
subject with an IENF density of 7.9 ﬁ-
bers/mm (Fig. 1B and D).
Pathologic and functional correlates
of CHEP in diabetic neuropathy
To explore the factors associated with
CHEP parameters in type 2 diabetic neu-
ropathy, we analyzed the effects of age,
sex,diabetesduration(seethe RESULTSsec-
tion in the online appendix), IENF den-
sity, and thermal thresholds. On simple
linear regression analyses, the CHEP am-
plitude was linearly correlated with the
IENF density (P  0.001, supplementary
Fig. A1) and cold threshold at foot dor-
sum(P0.049).Wethenanalyzedthese
relationships with a multiple linear re-
gressionmodel.TheIENFdensitywasthe
only independent variable that was still
linearly correlated with the CHEP ampli-
tude (P  0.003) (Table 1).
Tofurtherinvestigatetherelationship
between CHEP amplitude and IENF den-
sity and to determine the most important
parameters related to skin denervation,
we performed simple and multiple linear
regression analyses. In the simple linear
regression model, the IENF density was
correlatedwiththeCHEPamplitude(P
0.001)andwarmthresholds(P0.015).
On analysis with a multiple linear regres-
sion model, only the CHEP amplitude
was still correlated with the IENF density
(Table 1). Taken together, CHEP ampli-
tude was the most signiﬁcant neurophys-
iological correlate of the skin denervation
in type 2 diabetic neuropathy.
We then analyzed the association be-
tween pain perception to contact heat
stimuli and parameters of various exami-
nations. The intensity of pain perception
measured by verbal rating scale was cor-
related with the CHEP amplitude (P 
0.001), IENF density (P  0.004), warm
threshold (P  0.047), and cold thresh-
old (P  0.008) in simple linear regres-
sion. These relationships were reﬁned
with multiple linear regression models,
Figure 1—CHEP and skin innervation in type 2 diabetic neuropathy. Skin biopsies were stained
withanti-proteingeneproduct9.5(PGP9.5)antiserum,andIENFdensitieswerequantiﬁed.Skin
innervation and CHEP in a representative patient with type 2 diabetic neuropathy (A and C)
compared with an age- and sex-matched subject (B and D) are illustrated. A: Skin biopsy from a
60-year-old female patient shows marked depletion of cutaneous nerve terminals in the epidermis
(epi) with an IENF density of 0.9 ﬁbers/mm. Only loose and fragmented subepidermal nerve
bundles (sn) are recognizable in the dermis (derm). B: Skin biopsy from a 58-year-old healthy
woman shows varicose PGP 9.5() IENFs (arrows) in the epidermis with an IENF density of 7.9
ﬁbers/mm.CandD:AveragedtracingoftheCHEP(C)fromthepatientinAshowsattenuationof
N- and P-waves and relatively prolonged N-wave latency comparing with the well-deﬁned com-
plex of N- and P-waves (D) from the control subject in B. (For A and B, bar  25 m; for C and
D, time base  250 ms and sensitivity  50 V.)
Table 1—Correlation among CHEP, IENF density, and thermal thresholds on multiple linear
regression models
CHEP
amplitude IENF density
Verbal
rating scale
(CHEP amplitude)
Verbal
rating scale
(IENF density)
Model (R
2, P) 0.49, 0.006* 0.51, 0.004* 0.44, 0.017* 0.39, 0.04*
Independent variable
(, P)
Age 0.219, 0.337 0.007, 0.751 0.022, 0.383 0.015, 0.553
Sex 0.033, 0.995 0.343, 0.495 0.077, 0.897 0.141, 0.823
Duration of
diabetes
0.174, 0.647 0.028, 0.421 0.044, 0.291 0.045, 0.303
IENF density 6.045, 0.003* — — 0.409, 0.062
CHEP amplitude — 0.05, 0.003* 0.046, 0.019* —
Warm threshold 0.308, 0.652 0.061, 0.322 0.05, 0.498 0.027, 0.727
Cold threshold 0.325, 0.286 0.00,002, 0.999 0.03, 0.373 0.042, 0.227
,standardizedcoefﬁcientwithPforeachindependentvariable;CHEPamplitude,N-PamplitudeofCHEP;
R
2, covariance of the given multiple linear regression model with P for the model. *Statistically signiﬁcant.
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icantly correlated with pain perception
(standardized coefﬁcient 0.046, P 
0.019; R
2  0.44 and P  0.017 for the
model).
Relationship of the neuropathic pain
with CHEP and IENF density
To explore whether CHEP reﬂected the
neuropathicpainindiabetes,weanalyzed
the excitability indexes by calculating the
ratio of CHEP amplitude to IENF density.
The excitability index was signiﬁcantly
higher in the diabetic neuropathic group
than the age- and sex-matched control
group (44.03  97.31 vs. 3.95  1.02;
P  0.023), indicating relatively higher
CHEPamplitudescomparedwiththecor-
responding IENF densities in diabetic
painful neuropathy.
We further examined the relation-
ships between the CHEP amplitude and
different neuropathic pain symptoms by
analyzing the CHEP amplitude and IENF
density between patients with or without
a deﬁned symptom (Table 2). Among all
symptoms, the CHEP amplitude was
higher in patients with evoked pain than
in individuals without evoked pain
(24.9  14.8 vs. 10.2  14 V, P 
0.011); the degree of skin innervation be-
tweenthesetwosubgroups,however,was
similar, with IENF densities of 1.1  1.1
versus 1.1  1.6 ﬁbers/mm (P  0.989).
Thisﬁndingindicatedenhancedbrainac-
tivations relative to the corresponding
IENF density in patients with evoked
pain.
CONCLUSIONS— This study dem-
onstrates the clinical signiﬁcance of the
CHEP in type 2 diabetic neuropathy. Im-
portant ﬁndings include the following: 1)
abnormal CHEP patterns (reduction of
CHEP amplitudes or prolongation of
CHEP latencies) were noted in most pa-
tients(81.3%)ofdiabeticpainfulneurop-
athy with skin denervation, and these
ﬁndings could be neurophysiological
characteristics in diagnosing small-ﬁber
sensory neuropathy; 2) the CHEP ampli-
tude was the most signiﬁcant parameter
correlated with the IENF density and the
pain perception to contact heat stimuli
and could represent the physiological
consequences of thermonociceptive
nerve degeneration; and 3) patients with
diabetic painful neuropathy had much
higher CHEP amplitude relative to their
corresponding IENF densities, especially
the patients with evoked pain despite a
similar degree of skin denervation. These
observations suggest that the CHEP am-
plitude provides a noninvasive test for
assessing the degeneration of A ther-
monociceptive ﬁbers and reﬂects the
physiology of pain in type 2 diabetic
neuropathy.
This study is the ﬁrst to demonstrate
the feasibility of CHEP as a clinical exam-
ination for diabetic neuropathy. A nega-
tive-positive waveform of CHEP
mediated by A ﬁbers can be recorded in
normal subjects by suprathreshold and
ﬁxed-intensity thermal stimuli (10,15).
Because CHEPs record the brain activities
to heat pain stimuli conveyed by ther-
monociceptive nerves, they could detect
the dysfunctions due to small-diameter
sensory nerve degeneration. In patients
with skin denervation, the CHEP ampli-
tudes were reduced and the latencies be-
came prolonged (12,16). The present
study explores the clinical applications of
CHEP for the diagnosis of small-ﬁber
thermonociceptive nerve involvement in
diabetic neuropathy. In our diabetic pa-
tients with neuropathic pain and skin de-
nervation, 81.3% of patients had reduced
CHEP amplitudes or prolonged CHEP la-
tencies. These ﬁndings demonstrate that
CHEP can detect physiological conse-
quences of thermonociceptive nerve de-
generation and provide an objective,
sensitive, and noninvasive assessment for
thermonociceptive nerves in diabetes.
In the present study, the CHEP am-
plitude, IENF density, and thermal
thresholds were associated with one an-
other, and the only and most signiﬁcant
correlation existed between the CHEP
amplitude and IENF density on multiple
regression models. The generation of
CHEP begins at the cutaneous nocicep-
tors,andthesignalistransmittedthrough
A afferents to the central nerve system.
A ﬁbers lose their myelin sheath before
enteringtheepidermisandbecomeindis-
tinguishable from C-ﬁber terminals (17),
and the IENF density represents the pa-
thology of these small-diameter sensory
nerves terminating in the skin. Diabetic
neuropathy is associated with axonal de-
generation of C and A ﬁbers and skin
denervation (9,18). Therefore, reduced
IENF density might reﬂect pathological
changes in A afferents of peripheral
nerves and result in decreased input of
contact heat stimuli. In this study, CHEP
has the highest correlation with the IENF
density compared with other parameters
of sensory nerve functions such as ther-
mal thresholds in quantitative sensory
testing. This ﬁnding suggests that the
CHEP amplitude may serve as an alterna-
tive examination of thermonociceptive
nerves for diabetic patients in whom the
skin biopsy is contraindicated.
Table 2—CHEP amplitude and IENF density according to neuropathic pain symptoms
n CHEP amplitude P IENF density P
Evoked pain
Yes 10 24.9  14.8 0.011* 1.1  1.1 0.989
No 22 10.2  14 1.1  1.6
Tingling or shooting
Yes 25 15.4  15.6 0.67 1.1  1.6 0.74
No 7 12.5  16.8 0.9  1.0
Lacerating†
Yes 2 9  12.7 0.687 2.1  2.9 0.687
No 30 15.2  15.9 1.0  1.4
Hot or burning
Yes 13 17.1  18.2 0.51 1.5  1.8 0.139
No 19 13.3  13.9 0.7  1.2
Cold or freezing†
Yes 4 14.9  4.3 0.68 0.5  0.7 0.836
No 28 14.8  16.6 1.1  1.5
Electric shock
Yes 14 18.5  15.9 0.242 1.5  1.8 0.147
No 18 11.9  15.1 0.7  1.1
Numbness
Yes 25 14  13.9 0.608 0.9  1.3 0.255
No 7 17.5  21.8 1.6  2
Data are means  SD unless otherwise indicated. P, P value for the t test or nonparametric test. *Statistically
signiﬁcant. †Nonparametric test (Wilcoxon rank sum test).
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betic neuropathy (1), but the relationship
between skin denervation and neuro-
pathicpainisnotconsistent(19).Theob-
servation of higher CHEP amplitude
relative to the corresponding IENF den-
sity in patients with diabetic painful neu-
ropathy provides new insights about
mechanisms of neuropathic pain. Previ-
ous and the present studies documented
the positive correlation between the
CHEP amplitude and IENF density in
small-ﬁber neuropathy (16). Pain- or la-
ser-evoked potential also showed delayed
and reduced late responses in HIV-
associated neuropathy (20) and posther-
petic neuralgia (21). All these studies
showing attenuated or delayed responses
of pain-related potentials indicated deaf-
ferentation of peripheral A ﬁber nerves
(22). CHEPs represent the brain activities
that are affected not only by peripheral
deafferentation but also by the changes in
central processing through the spinal
cordandbrain.Inthisstudy,wedesigned
an excitability index to assess the signiﬁ-
cance of CHEP amplitude in relation to
the corresponding IENF density. Patients
withdiabeticpainfulneuropathyandskin
denervation had higher excitability in-
dexesthancontrolsubjects.Furthermore,
the analysis of subgroups with different
features of neuropathic pain demon-
strated higher CHEP amplitudes in the
subgroup with evoked pain than the
group without this symptom, despite a
similar degree of cutaneous nerve degen-
eration. These ﬁndings indicate that pa-
tients with diabetic painful neuropathy
had relatively enhanced brain activities of
CHEP, even with corresponding reduc-
tion of IENF densities, and suggest that
the CHEP amplitude could serve as a
physiological hallmark of evoked pain in
diabeticpainfulneuropathy.Thepossible
mechanisms underlying such changes in
CHEP include both peripheral sensitiza-
tion at the level of the peripheral nerve
and dorsal root ganglia and central sensi-
tization at the spinal and supraspinal lev-
els during the progression of diabetic
neuropathy. For example, upregulation
and enhanced activities of voltage-gated
sodium channels, or transient receptor
potential vanilloid 1 receptor, increased
noradrenergic sensitivity of human noci-
ceptors and plasticity in the spinal cord
involving GABA receptors, NMDA recep-
tors, or nitric oxide synthase–nitric oxide
cascade. Additional supraspinal inﬂu-
ences also contribute to the development
and maintenance of thermal hyperalgesia
(23,24). The present study demonstrates
the opportunity of applying CHEP as a
tool to follow the progression of neurop-
athy and to investigate whether such
changes parallel the progression of symp-
toms and disability. This study speciﬁcally
focused on diabetic painful neuropathy.
The extension of this approach to nonpain-
ful neuropathy will provide further insights
on the relations between CHEP and clinical
symptoms.
In conclusion, CHEP provides a non-
invasive and sensitive approach to assess
the involvement of thermonociceptive
nervesindiabeticpatientsandalsoprovides
physiological evidence of evoked pain.
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